Sana Biotechnology Inc. Watch

EX-10.2

from 10-Q 4 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Pursuant to Item 601(b)(10)(iv) of Regulation S-K Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Treats as Private or Confidential. Sixth Amendment to License Agreement

12/34/56

EX-10.1

from 10-Q 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Pursuant to Item 601(b)(10)(iv) of Regulation S-K Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Treats as Private or Confidential. Amendment No. 2 to Amended and Restated Exclusive Patent License Agreement

12/34/56

EX-10.2

from 10-Q 10 pages Personal & Confidential April 15, 2024 Douglas E. Williams (By Email) Re: Separation, Transition Services, and General Release Agreement 1

12/34/56

EX-10.1

from 10-Q 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Pursuant to Item 601(b)(10)(iv) of Regulation S-K Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Treats as Private or Confidential. Second Amendment to the License Agreement Uc Control Number [***]

12/34/56

EX-10.1

from 10-Q 5 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Pursuant to Item 601(b)(10)(iv) of Regulation S-K Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Treats as Private or Confidential. Amendment No. 4 to Option and License Agreement

12/34/56

EX-10.21(B)

from 10-K 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Pursuant to Item 601(b)(10)(iv) of Regulation S-K Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Treats as Private or Confidential. Amendment No. 1 to Amended and Restated Exclusive Patent License Agreement

12/34/56

EX-10.16(B)

from 10-K 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Pursuant to Item 601(b)(10)(iv) of Regulation S-K Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Treats as Private or Confidential. First Amendment to the Exclusive License Agreement Uc Control Number [***]

12/34/56

EX-10.29

from 10-K 16 pages Sana Biotechnology, Inc. Change in Control Severance Plan and Summary Plan Description (Amended February 27, 2024) 1

12/34/56

EX-10.1

from 10-Q 3 pages Certain Confidential Information in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Amendment No. 3 to Patents Sub-License Agreement

12/34/56

EX-10.4

from 10-Q 11 pages Consulting Agreement

12/34/56

EX-10.3

from 10-Q 23 pages April 15, 2023 Sunil Agarwal [***] [***] Re: Transition Agreement and Release Dear Sunil,

12/34/56

EX-10.2

from 10-Q 7 pages April 8, 2023 Douglas E. Williams [***] [***] Sent via Email to [***] Re: Employment Terms

12/34/56

EX-10.1

from 10-Q 5 pages Certain Confidential Information in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Amendment No. 3 to Option and License Agreement

12/34/56

EX-10.22(C)

from 10-K 3 pages Certain Confidential Information in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Amendment No. 2 to Non-Exclusive License and Development Agreement

12/34/56

EX-10.22(B)

from 10-K 3 pages Certain Confidential Information in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Amendment No. 1 to Non-Exclusive License and Development Agreement

12/34/56

EX-10.16(F)

from 10-K 3 pages Certain Confidential Information in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Fifth Amendment to License Agreement

12/34/56

EX-10.12

from 10-K 5 pages Sana Biotechnology, Inc. Non-Employee Director Compensation Program Adopted April 4, 2022

12/34/56

EX-10.11

from 10-Q 1 page Sana Biotechnology, Inc. 2021 Employee Stock Purchase Plan Amendment

12/34/56

EX-10.10

from 10-Q 6 pages September 8, 2022 Bernard Cassidy [***] [***] Sent via Email to [***] Re: Employment Terms

12/34/56

EX-10.9

from 10-Q 3 pages Certain Confidential Information in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Amendment No. 11 to Exclusive Start-Up License Agreement Between Cytocardia, Inc. and University of Washington

12/34/56